Pulse 探索 nav.journalClub 議論トレンド研究者

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

ホーム探索 nav.journalClub トレンド

⌘+K

Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study | Synapse

July 1, 2024

Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study

Key Points

Key points are not available for this paper at this time.

Abstract

To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE).

AIに質問

Like

Bookmark

Share

Cite This Study

Tani et al. (Mon,) studied this question.

synapsesocial.com/papers/68e61de3b6db6435875af9a9 https://doi.org/https://doi.org/10.3899/jrheum.2024-0053

AIに質問

Like

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus2023 · 54 citations
2Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)2015 · 739 citations
3Treatment With Anifrolumab for Discoid Lupus Erythematosus2022 · 30 citations
42021 DORIS definition of remission in SLE: final recommendations from an international task force2021 · 356 citations
5Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus2016 · 868 citations